RU2002129298A - Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера - Google Patents

Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера Download PDF

Info

Publication number
RU2002129298A
RU2002129298A RU2002129298/14A RU2002129298A RU2002129298A RU 2002129298 A RU2002129298 A RU 2002129298A RU 2002129298/14 A RU2002129298/14 A RU 2002129298/14A RU 2002129298 A RU2002129298 A RU 2002129298A RU 2002129298 A RU2002129298 A RU 2002129298A
Authority
RU
Russia
Prior art keywords
dose
day
galantamine
administered
use according
Prior art date
Application number
RU2002129298/14A
Other languages
English (en)
Russian (ru)
Inventor
Вим Луи Жюльен ПАРИС (US)
Вим Луи Жюльен ПАРИС
Майкл ПОНТЕКОРВО (US)
Майкл ПОНТЕКОРВО
Original Assignee
Янссен Фармацевтика Н.В. (Be)
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. (Be), Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В. (Be)
Publication of RU2002129298A publication Critical patent/RU2002129298A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2002129298/14A 2000-04-03 2001-03-28 Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера RU2002129298A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
US60/194,259 2000-04-03

Publications (1)

Publication Number Publication Date
RU2002129298A true RU2002129298A (ru) 2004-03-27

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002129298/14A RU2002129298A (ru) 2000-04-03 2001-03-28 Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера

Country Status (20)

Country Link
EP (1) EP1272192A2 (xx)
JP (1) JP2003528913A (xx)
KR (1) KR20020086911A (xx)
CN (1) CN1430514A (xx)
AU (2) AU6584401A (xx)
BG (1) BG107093A (xx)
BR (1) BR0109770A (xx)
CA (1) CA2310926C (xx)
CZ (1) CZ20023543A3 (xx)
EE (1) EE200200554A (xx)
HR (1) HRP20020778A2 (xx)
HU (1) HUP0300566A3 (xx)
IL (1) IL152061A0 (xx)
MX (1) MXPA02009777A (xx)
NO (1) NO20024746L (xx)
PL (1) PL361272A1 (xx)
RU (1) RU2002129298A (xx)
SK (1) SK15422002A3 (xx)
WO (1) WO2001074339A2 (xx)
ZA (1) ZA200207935B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
EP1651234B1 (en) 2003-07-25 2007-09-26 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
AU2009229372C1 (en) 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
WO2016187339A1 (en) * 2015-05-18 2016-11-24 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOIDß
CN117957003A (zh) * 2021-09-09 2024-04-30 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
ES2211215T3 (es) * 1998-12-24 2004-07-01 Janssen Pharmaceutica N.V. Composicion de galantamina de liberacion controlada.
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects

Also Published As

Publication number Publication date
EE200200554A (et) 2004-04-15
CA2310926A1 (en) 2000-10-04
PL361272A1 (en) 2004-10-04
AU2001265844B2 (en) 2005-04-14
BR0109770A (pt) 2003-02-04
SK15422002A3 (sk) 2003-04-01
HUP0300566A3 (en) 2004-10-28
AU6584401A (en) 2001-10-15
ZA200207935B (en) 2004-01-30
MXPA02009777A (es) 2003-03-27
CZ20023543A3 (cs) 2003-03-12
BG107093A (bg) 2003-06-30
IL152061A0 (en) 2003-05-29
HUP0300566A2 (hu) 2003-06-28
CN1430514A (zh) 2003-07-16
EP1272192A2 (en) 2003-01-08
CA2310926C (en) 2002-10-15
WO2001074339A3 (en) 2002-09-12
KR20020086911A (ko) 2002-11-20
WO2001074339A2 (en) 2001-10-11
NO20024746L (no) 2002-11-28
JP2003528913A (ja) 2003-09-30
HRP20020778A2 (en) 2004-04-30
NO20024746D0 (no) 2002-10-02

Similar Documents

Publication Publication Date Title
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2089027T3 (es) Forma de dosificacion transmucosica.
RU2008116931A (ru) Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
JP2005515966A5 (xx)
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
RU2002121546A (ru) Вещества, предназначенные для лечения псориаза
JP2004537500A5 (xx)
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
EP1372682A4 (en) CATECHINS FOR THE TREATMENT OF FIBRILLOGENESIS IN ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SYSTEMIC AMYLOSIS AA, AND OTHER AMYLOID DISORDERS
JP2002544233A5 (xx)
JP2002540148A5 (xx)
JP2003514025A5 (xx)
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
RU2003100081A (ru) Способы и композиции, в которых используется сулодексид, для лечения диабетической нефропатии
JP2003523385A5 (xx)
CA2368352A1 (en) Method for treating neurodegeneration
RU95112520A (ru) Применение 4'-йодо-4'-деоксидоксорубицина для лечения амилоидоза, способ лечения амилоидоза
RU2006110550A (ru) Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин
CA2403674A1 (en) The use of t3 for treating congestive heart failure
AR020167A1 (es) Metodo para la prevencion del inicio del asma
RU2001128509A (ru) Способ лечения нейродегенерации
KR890001558A (ko) 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염
DE60210804D1 (de) Verwendung von propionyl-l-carnitin oder dessen pharmakologisch akzeptabler salze zur herstellung eines medikamentes zur behandlung von la peyronie's krankheit

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060405